Barclays’s Intersect ENT, Inc XENT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-355,531
| Closed | -$9.96M | – | 5503 |
|
|
2022
Q1 | $9.96M | Buy |
355,531
+276,337
| +349% | +$7.57M | 0.01% | 906 |
|
|
2021
Q4 | $2.16M | Sell |
79,194
-34,320
| -30% | -$930K | ﹤0.01% | 2337 |
|
|
2021
Q3 | $3.09M | Buy |
113,514
+84,980
| +298% | +$2.1M | ﹤0.01% | 1992 |
|
|
2021
Q2 | $487K | Sell |
28,534
-164,171
| -85% | -$3.07M | ﹤0.01% | 3088 |
|
|
2021
Q1 | $4.02M | Buy |
192,705
+93,037
| +93% | +$2.15M | ﹤0.01% | 1706 |
|
|
2020
Q4 | $2.28M | Buy |
99,668
+65,554
| +192% | +$1.25M | ﹤0.01% | 2133 |
|
|
2020
Q3 | $556K | Sell |
34,114
-108,156
| -76% | -$1.96M | ﹤0.01% | 3162 |
|
|
2020
Q2 | $1.93M | Sell |
142,270
-26,262
| -16% | -$306K | ﹤0.01% | 2157 |
|
|
2020
Q1 | $2M | Sell |
168,532
-333,119
| -66% | -$7.39M | ﹤0.01% | 2286 |
|
|
2019
Q4 | $12.5M | Buy |
501,651
+173,833
| +53% | +$3.52M | 0.01% | 1236 |
|
|
2019
Q3 | $5.58M | Buy |
327,818
+134,280
| +69% | +$2.44M | ﹤0.01% | 1756 |
|
|
2019
Q2 | $4.41M | Buy |
193,538
+70,991
| +58% | +$1.91M | ﹤0.01% | 1989 |
|
|
2019
Q1 | $3.94M | Buy |
122,547
+107,928
| +738% | +$3.34M | ﹤0.01% | 1866 |
|
|
2018
Q4 | $412K | Sell |
14,619
-26,391
| -64% | -$773K | ﹤0.01% | 3981 |
|
|
2018
Q3 | $1.18M | Buy |
41,010
+36,997
| +922% | +$1.11M | ﹤0.01% | 3477 |
|
|
2018
Q2 | $150K | Sell |
4,013
-2,112
| -34% | -$82.9K | ﹤0.01% | 4972 |
|
|
2018
Q1 | $241K | Sell |
6,125
-20,133
| -77% | -$735K | ﹤0.01% | 4672 |
|
|
2017
Q4 | $851K | Buy |
26,258
+2,942
| +13% | +$88.2K | ﹤0.01% | 3271 |
|
|
2017
Q3 | $727K | Buy |
23,316
+5,694
| +32% | +$169K | ﹤0.01% | 3282 |
|
|
2017
Q2 | $492K | Buy |
17,622
+699
| +4% | +$15.8K | ﹤0.01% | 3546 |
|
|
2017
Q1 | $290K | Sell |
16,923
-283,380
| -94% | -$3.97M | ﹤0.01% | 3956 |
|
|
2016
Q4 | $3.63M | Buy |
300,303
+296,254
| +7,317% | +$3.84M | ﹤0.01% | 1616 |
|
|
2016
Q3 | $65K | Buy |
4,049
+2,526
| +166% | +$38K | ﹤0.01% | 4824 |
|
|
2016
Q2 | $20K | Sell |
1,523
-1,248
| -45% | -$19.5K | ﹤0.01% | 5277 |
|
|
2016
Q1 | $53K | Sell |
2,771
-2,519
| -48% | -$45.6K | ﹤0.01% | 4731 |
|
|
2015
Q4 | $116K | Buy |
5,290
+5,204
| +6,051% | +$103K | ﹤0.01% | 4309 |
|
|
2015
Q3 | $2K | Sell |
86
-182
| -68% | -$5.02K | ﹤0.01% | 6411 |
|
|
2015
Q2 | $8K | Buy |
268
+87
| +48% | +$2.28K | ﹤0.01% | 6227 |
|
|
2015
Q1 | $5K | Sell |
181
-1,953
| -92% | -$44.7K | ﹤0.01% | 6614 |
|
|
2014
Q4 | $38K | Buy |
+2,134
| New | +$38.4K | ﹤0.01% | 5924 |
|
Barclays's XENT Position: Q2 2022 in Review
Barclays sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 355,531 shares — an estimated $9.96M sold.
Barclays first reported a position in XENT in Q4 2014 and held it in 30 quarters. The position peaked at $12.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.
- Barclays reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
- Barclays sold 355,531 Intersect ENT, Inc shares in Q2 2022, an estimated $9.96M.
- Barclays first reported a position in Intersect ENT, Inc in Q4 2014 and held it in 30 quarters.
- Barclays's Intersect ENT, Inc position peaked at $12.5M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.
Based on Barclays's 13F filing for Q2 2022, filed 12 Aug 2022.